Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 205 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lipoprotein Disorder Clear all
Completed Phase 2 Interventional Results available

A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

NCT05565742
View directory record Official record
Conditions
Lipoprotein Disorder
Interventions
LY3819469, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Mesa, Arizona • Pasadena, California • Santa Clarita, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

NCT01323153
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
dalcetrapib, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
45 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Pensacola, Florida • Saginaw, Michigan • Saint Cloud, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jul 22, 2026, 9:34 AM EDT
Active, not recruiting Not applicable Interventional

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management

NCT05088759
View directory record Official record
Conditions
Hyperlipemia, Mixed, ASCVD
Interventions
Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Amino Acids on Regional Lipid Metabolism

NCT01150188
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Amino acids, Placebo
Dietary Supplement
Lead sponsor
University of Arkansas
Other
Eligibility
50 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jul 22, 2026, 9:34 AM EDT
Completed No phase listed Observational

The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)

NCT01778569
View directory record Official record
Conditions
Metabolic Disease, Cardiovascular Disease, Inflammation, Psoriasis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

NCT02392559
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 17 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
12
States / cities
Farmington, Connecticut • Wilmington, Delaware • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Phase 4 Interventional Results available

Lovaza® and Microvascular Function in Type 2 Diabetes

NCT00931879
View directory record Official record
Conditions
Hypertriglyceridemia, Diabetic Neuropathy
Interventions
omega-3-ethyl esters, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

NCT01262118
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 (tasocitinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
9
States / cities
Anniston, Alabama • Little Rock, Arkansas • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Consuming Palm Oil With Different Macronutrient Intakes on Blood Lipids

NCT02922062
View directory record Official record
Conditions
Cardiovascular Diseases, Inflammation
Interventions
Canola Oil, Palm Oil, Butter
Other
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Not applicable Interventional Results available

(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol

NCT00526058
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Secura then Futura, Futura then Secura
Device
Lead sponsor
B. Braun Medical Inc.
Industry
Eligibility
25 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Hartford, Connecticut • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

NCT02597127
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Nutritional Supplement Effect on HDL Function

NCT04529174
View directory record Official record
Conditions
HDL
Interventions
CardioLux™HDL, Placebo
Dietary Supplement
Lead sponsor
Metagenics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Phase 4 Interventional

Evaluation of Combination Cholesterol Treatments in Patients With High Cholesterol.

NCT00249938
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia
Interventions
Minute Maid Heart Wise orange juice, Welchol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Not applicable Interventional

The Effect of Vitamin D Repletion on Small Low Density Lipoprotein (LDL) Particle Number in Subjects at Elevated Cardiovascular Risk

NCT01008384
View directory record Official record
Conditions
Atherosclerosis
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Jul 22, 2026, 9:34 AM EDT
Withdrawn Phase 4 Interventional

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

NCT01180764
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza (Omega-3 acid ethyl esters), Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jul 22, 2026, 9:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Asymptomatic Carotid Atherosclerosis Between Frequent and Infrequent Blood Donors

NCT00001589
View directory record Official record
Conditions
Carotid Atherosclerosis, Myocardial Infarction
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

NCT05787002
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Not applicable Interventional

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

NCT05378529
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Lp(a) Screening
Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
39,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
113
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 22, 2026, 9:34 AM EDT
Recruiting Phase 3 Interventional

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

NCT07293260
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Olpasiran, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
35 Years to 80 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Bridgeport, Connecticut • Jacksonville, Florida • Overland Park, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes

NCT01156597
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pioglitazone
Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers

NCT00175084
View directory record Official record
Conditions
Hyperlipidemias, Metabolic Syndrome X, Cardiovascular Diseases
Interventions
Comparison of dietary protein amino acid profile
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides

NCT00108511
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Gemfibrozil
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
19 Years to 74 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

NCT01865812
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Jul 22, 2026, 9:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Fat and High-Density Lipoprotein (HDL) Metabolism-Effect of Carbohydrate and Fat Intake

NCT01399632
View directory record Official record
Conditions
Overweight, Cardiovascular Diseases
Interventions
Low Fat and High Carbohydrate Diet, High Fat and Low Carbohydrate Diet
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jul 22, 2026, 9:34 AM EDT